JonesTrading analyst Soumit Roy reiterated a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price
Author: Christine Brown
Stifel Nicolaus Believes Fire & Flower Holdings (Other OTC: FFLWF) Won’t Stop Here
In a report released today, Justin Keywood from Stifel Nicolaus initiated coverage with a Buy rating on Fire & Flower
Fate Therapeutics (FATE) Receives a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Fate Therapeutics (FATE – Research Report) on February 26. The
Endo International (ENDP) Gets a Hold Rating from Leerink Partners
Leerink Partners analyst Ami Fadia maintained a Hold rating on Endo International (ENDP – Research Report) on February 25. The
Leerink Partners Maintains Their Hold Rating on Satsuma Pharmaceuticals (STSA)
In a report released yesterday, Marc Goodman from Leerink Partners maintained a Hold rating on Satsuma Pharmaceuticals (STSA – Research
H.C. Wainwright Keeps a Buy Rating on BiomX (PHGE)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BiomX (PHGE – Research Report) today and set a price
Robert W. Baird Believes MasTec (NYSE: MTZ) Still Has Room to Grow
In a report released yesterday, Andrew Wittmann from Robert W. Baird maintained a Buy rating on MasTec (MTZ – Research